Neurostimulation platform company targeting chronic migraines Salvia BioElectronics announced on Tuesday that it has raised EUR 26 million ($31 million) in new financing from new and existing investors.
Neurostimulation has been proven effective in treating in chronic migraines, but there are no approved implantable devices available on the market. Salvia BioElectronics is developing highly conforming bioelectronic foils that can be inserted below the skin in a minimally invasive procedure.
Migraine is the leading cause of disability in people under age 50, affecting one out of seven people, predominantly women. Patients experience episodes of throbbing, pulsating pain, sometimes accompanied by nausea, vomiting, and sensitivity to light. Migraines can last anywhere from a few hours to a few days.
